Stockscreener 앱 받기
19.94
2.87%
-0.59
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Apellis stock crashes 23% in a week: Here's what you should know - MSN
Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases - MSN
Is Apellis Pharmaceuticals’ FDA Win Just the Beginning? - Yahoo Finance
Market Trends: Does Apellis Pharmaceuticals Inc stock have upside surprise potential2025 Stock Rankings & Capital Efficient Trading Techniques - baoquankhu1.vn
Apellis stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com UK
Apellis Pharma VP Chopas sells $19k in shares By Investing.com - Investing.com Canada
Apellis Pharma chief business officer sells $39k in APLS stock - Investing.com Canada
Mark Jeffrey Delong Sells 1,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells $19,371.87 in Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CFO Sells 3,856 Shares of Stock - MarketBeat
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells 2,618 Shares of Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) CEO Sells $226,027.34 in Stock - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Insider Pascal Deschatelets Sells 2,277 Shares - MarketBeat
David Watson Sells 5,780 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock - MarketBeat
Apellis Pharma CFO Sullivan sells $85,553 in shares By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $128k in shares By Investing.com - Investing.com Canada
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Press Telegram - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 5.8% on Analyst Downgrade - MarketBeat
Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - sharewise.com
Assessing Apellis Pharmaceuticals (APLS) Valuation After 2025 Revenue Update And Pipeline Progress - Sahm
Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS) - Yahoo Finance
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
APLS: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
Cantor Fitzgerald Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $35.00 - MarketBeat
Forecasting The Future: 9 Analyst Projections For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $28.00 by Analysts at Needham & Company LLC - MarketBeat
Needham lowers Apellis Pharmaceuticals stock price target on Syfovre concerns - Investing.com UK
Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
APLS: Needham Maintains Buy Rating, Lowers Price Target to $28 | - GuruFocus
A Look At Apellis Pharmaceuticals (APLS) Valuation After Strong 2025 Revenue Update And Nephrology Expansion - Yahoo Finance
Apellis Pharmaceuticals (APLS) Stock Analysis: A 50% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Strategic Updates - TradingView — Track All Markets
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's What Happened - MarketBeat
Apellis Pharmaceuticals (APLS) Is Up 9.8% After Strong SYFOVRE Demand Lifts Preliminary 2025 Revenues - Sahm
Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference - MarketBeat
Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference - TechStock²
Goldman Sachs reiterates Sell rating on Apellis stock amid revenue miss - Investing.com Canada
Apellis (APLS) Shares Plummet Over 17% - GuruFocus
Apellis Pharmaceuticals Reports Preliminary 2025 Revenues of $689 Million, Highlights Growth in SYFOVRE and EMPAVELI Sales - Quiver Quantitative
Apellis Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
SG Americas Securities LLC Purchases 372,289 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Why (APLS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE? - simplywall.st
Aug Breakouts: Is Apellis Pharmaceuticals Inc. stock near bottom after declineMarket Performance Recap & Daily Price Action Insights - ulpravda.ru
Can Apellis Pharmaceuticals Inc. stock sustain institutional interest2025 Investor Takeaways & AI Powered Buy/Sell Recommendations - ulpravda.ru
Can Apellis Pharmaceuticals Inc. (1JK) stock surprise with quarterly resultsJuly 2025 Weekly Recap & Risk Managed Investment Strategies - Улправда
Will Apellis Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Trends & Weekly Watchlist for Consistent Profits - Улправда
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersBlue Chip Stock Analysis & Superior Wealth Strategies - bollywoodhelpline.com
How buybacks impact Apellis Pharmaceuticals Inc. stock value2025 Buyback Activity & Smart Swing Trading Techniques - Улправда
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekers - ulpravda.ru
Apellis Pharmaceuticals (NASDAQ:APLS) Trading 7.8% HigherWhat's Next? - MarketBeat
Apellis stock jumps nearly 8% as investors look to JPM healthcare update - TechStock²
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Navigating a 40.73% Potential Upside in the Biotech Space - DirectorsTalk Interviews
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN
Resistance Check: Is Apellis Pharmaceuticals Inc stock cheap at current valuation2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Simplify Asset Management Inc. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Institution Moves: How buybacks impact Apellis Pharmaceuticals Inc stock valueJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - moha.gov.vn
Apellis Pharmaceuticals' chief commercial officer sells shares worth $101,103 - MSN
Understanding Momentum Shifts in (APLS) - Stock Traders Daily
Highland Capital Management LLC Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - bollywoodhelpline.com
4.73%
0.92%
자본화:
|
볼륨(24시간):